Skin Elements Strengthens Balance Sheet as Natural Antimicrobial Portfolio Moves Toward Commercial Launch

Skin Elements Limited ( (AU:SKN) ) has issued an update.

Skin Elements reported a strong December quarter as it readies its SE Formula-based product suite for commercial rollout, completing phase-three development across all five platforms and securing further validation through independent laboratory testing and extended field evaluations. The company finalised large-scale kiwifruit trials in New Zealand for its ECO-Nurture biostimulant, which is now on Zespri’s allowed compounds list and being prepared for a 2026 market launch, while its SuprCuvr hospital-grade disinfectant has been adopted by Spotless for daily cleaning on Melbourne’s metro rail network after a two-year assessment; combined with a A$2.5 million capital raising, a A$610,000 R&D rebate and the conversion of A$1 million in management remuneration into equity, these developments bolster Skin Elements’ balance sheet and support its transition from R&D focus to commercial scale sales in 2026.

The most recent analyst rating on (AU:SKN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Skin Elements Limited stock, see the AU:SKN Stock Forecast page.

More about Skin Elements Limited

Skin Elements Limited is an Australian biotechnology company specialising in all-natural, plant-based antimicrobial and GREEN-Tech formulations used across consumer, industrial and agricultural markets. Its proprietary SE Formula underpins a portfolio that includes Elizabeth Jane natural cosmetics, Soléo Organics sun protection, PapayaActivs therapeutic skincare, SuprCuvr hospital-grade disinfectants and ECO-Nurture horticultural biostimulants, all positioned as environmentally safe alternatives to traditional chemical-based products.

Current Market Cap: A$15M

Find detailed analytics on SKN stock on TipRanks’ Stock Analysis page.